A Study of OBIZUR in Adults With Acquired Hemophilia A (AHA) in South Korea

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

9 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-07-22

Study Completion Date

2026-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Acquired hemophilia A (AHA) is a rare bleeding condition which prevents blood clotting. Acquired means that people are not born with this condition or have a family history of blood clotting conditions. People living with AHA can have sudden and severe bleeding. They also have longer bleeding compared to people without AHA.

The main aim of the study is to learn how safe OBIZUR is in adults with AHA.

Other aims are to see how effective OBIZUR is to control bleeding and how treatment is used in a routine clinical practice setting.

The treatment of the participants will be determined by the treating physicians.

During the study, data already existing in the participants' medical record and new data will be collected.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Survey of Susoctocog Alfa (Genetical Recombination) in Participants With Acquired Haemophilia A

NCT06461533

Acquired Hemophilia A

RECRUITING

Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia A

NCT02610127

Acquired Hemophilia A

COMPLETED

The Safety of Emicizumab SC Injection in Korean Hemophilia A Patients With/Without FVIII Inhibitors

NCT04805801

Hemophilia A With Inhibitor Hemophilia A Without Inhibitor

UNKNOWN

An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A.

NCT04456387

Hemophilia A

COMPLETED PHASE3

To Investigate Safety and Efficacy of NovoEight® (rFVIII) During Long-term Treatment of Haemophilia A in Japan

NCT02207218

Congenital Bleeding Disorder Haemophilia A

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a prospective, and retrospective, multicenter, single-arm non-interventional post-marketing surveillance study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acquired Hemophilia A

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

All Participants

Participants with AHA who are receiving OBIZUR injection or initiate OBIZUR Injection treatment for the first time will be enrolled. Both retrospective and prospective participants data will be collected. Retrospective data will be collected from the date of first treatment with OBIZUR injection after the marketing authorization in Korea but before date of signed informed consent and prospective data will be collected from the date of signed informed consent. The treatment and follow up of the participants will be determined by the treating physicians according to her/his routine practice.

OBIZUR

Intervention Type DRUG

OBIZUR injection.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

OBIZUR

OBIZUR injection.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Susoctocog Alpha Porcine Antihemophilic factor VIII, Recombinant TAK-672

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participants with AHA.
* Participants who are determined to have the clinical need to receive Obizur treatment.
* Participants aged 18 years or older at time of initiation of Obizur treatment.
* Participants agreed to participate in the study and voluntarily signed the informed consent.

Exclusion Criteria

* Participants with hypersensitivity to any of the components of this drug.
* Participants with Congenital Hemophilia A with Inhibitors (CHAWI).
* Participants for whom Obizur treatment is contraindicated as per product label.
* Participants who has participated in another clinical study involving a medicinal product or device within 30 days prior to enrollment or is scheduled to participate in another clinical study involving a medicinal product or device during the course of the study.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No